G
Gerard J. Oakley
Researcher at Eli Lilly and Company
Publications - 28
Citations - 2644
Gerard J. Oakley is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Notch signaling pathway & Cancer. The author has an hindex of 13, co-authored 28 publications receiving 1485 citations. Previous affiliations of Gerard J. Oakley include University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.
Peter Chen,Ajay Nirula,Barry Heller,Robert L. Gottlieb,Joseph Boscia,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Lei Shen,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Daniel Skovronsky +21 more
TL;DR: In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11.
Journal ArticleDOI
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Robert L. Gottlieb,Ajay Nirula,Peter Chen,Joseph Boscia,Barry Heller,Jason Morris,Gregory D. Huhn,Jose Cardona,Bharat Mocherla,Valentina Stosor,Imad Shawa,Princy Kumar,Andrew C. Adams,Jacob Van Naarden,Kenneth L. Custer,Michael Durante,Gerard J. Oakley,Andrew E. Schade,Timothy R. Holzer,Philip J. Ebert,Richard E. Higgs,Nicole L. Kallewaard,Janelle Sabo,Dipak R. Patel,Paul Klekotka,Lei Shen,Daniel Skovronsky +26 more
TL;DR: The BLAZE-1 trial as mentioned in this paper evaluated the effect of bamlanivimab monotherapy and combination therapy on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19.
Journal ArticleDOI
Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis.
TL;DR: Evaluating the performance of new markers: brachyury, SOX-9, and podoplanin alongside the more traditional markers glial fibrillary acid protein, carcinoembryonic antigen, CD24, and epithelial membrane antigen found they did not outperform other markers, and are less useful in the diagnosis of chordoma vs chondrosarcoma.
Journal ArticleDOI
The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor–positive metastatic breast cancer
Seth A. Wander,Ofir Cohen,Ofir Cohen,Xueqian Gong,Gabriela N. Johnson,Gabriela N. Johnson,Jorge E. Buendia-Buendia,Jorge E. Buendia-Buendia,Maxwell R. Lloyd,Dewey Kim,Dewey Kim,Flora Luo,Pingping Mao,Karla Helvie,Kailey J. Kowalski,Kailey J. Kowalski,Utthara Nayar,Adrienne G. Waks,Stephen Parsons,Ricardo Martinez,Lacey M. Litchfield,Xiang S. Ye,Chunping Yu,Valerie M. Jansen,John R. Stille,Patricia S Smith,Gerard J. Oakley,Quincy Chu,Gerald Batist,Melissa E. Hughes,Jill D. Kremer,Levi A. Garraway,Eric P. Winer,Sara M. Tolaney,Nan Lin,Sean Buchanan,Nikhil Wagle +36 more
TL;DR: Whole exome sequencing of 59 tumors with CDK4/6i exposure revealed multiple candidate resistance mechanisms including RB1 loss, activating alterations in AKT1, RAS, AURKA, CCNE2, ERBB2, and FGFR2, which may define therapeutic opportunities in patients.
Journal ArticleDOI
First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer.
Christophe Massard,Analia Azaro,Analia Azaro,Jean-Charles Soria,Ulrik Lassen,C. Le Tourneau,C. Le Tourneau,C. Le Tourneau,Debashis Sarker,Claire Smith,Ute Ohnmacht,Gerard J. Oakley,Bharvin K. R. Patel,Eunice Yuen,Karim A. Benhadji,Jordi Rodon +15 more
TL;DR: Potent inhibition of Notch signaling by LY3039478 was well tolerated at doses associated with target engagement, and demonstrated evidence of clinical activity in heavily pretreated patients.